Resveratrol abrogates the effects of hypoxia on cell proliferation, invasion and EMT in osteosarcoma cellsthrough downregulation of the HIF-1α protein

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 1975-1981

  Sun, Yongming ^a   Wang, Haibin ^a   Liu, Ming ^a   Lin, Fanguo ^a   Hua, Jun ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Epithelial to mesenchymal transition; Hypoxia inducible factor 1 ; Invasion; Osteosarcoma; Resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RESVERATROL; SMALL INTERFERING RNA; UVOMORULIN; VIMENTIN; STILBENE DERIVATIVE;

ARTICLE; CELL GROWTH; CELL HYPOXIA; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SAOS 2 CELL LINE; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OSTEOSARCOMA; STILBENES;

EID: 84916620507     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2913     Document Type: Article

References (53)

1. Stiller CA: International patterns of cancer incidence in adolescents. Cancer Treat Rev 33: 631-645, 2007.
2. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600-1606, 1986.
3. Harting MT, Blakely ML, Jaffe N, et al: Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 41: 194-199, 2006.
4. Meyers PA, Heller G, Healey JH, et al: Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 11: 449-453, 1993.
5. Geller DS and Gorlick R: Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8: 705-718, 2010.
6. Michieli P: Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? Cell Cycle 8: 3291-3296, 2009.
7. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S and Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361, 2003.
8. Esteban MA, Tran MG, Harten SK, et al: Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 66: 3567-3575, 2006.
9. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
10. Cheng ZX, Sun B, Wang SJ, et al: Nuclear factor-B-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. PLoS One 6: e23752, 2011.
11. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8: S62-S67, 2002.
12. Imai T, Horiuchi A, Wang C, et al: Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163: 1437-1447, 2003.
13. Yang MH and Wu KJ: TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle 7: 2090-2096, 2008.
14. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
15. Gupta GP and Massague J: Cancer metastasis: building a framework. Cell 127: 679-695, 2006.
16. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693-4696, 2000.
17. Birner P, Schindl M, Obermair A, Breitenecker G and Oberhuber G: Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7: 1661-1668, 2001.
18. Aebersold DM, Burri P, Beer KT, et al: Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916, 2001.
19. Koukourakis MI, Giatromanolaki A, Skarlatos J, et al: Hypoxia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61: 1830-1832, 2001.
20. Soleas GJ, Diamandis EP and Goldberg DM: Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal 11: 287-313, 1997.
21. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-2840, 2004.
22. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J and Le AD: Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 4: 1465-1474, 2005.
23. Jang M, Cai L, Udeani GO, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997.
24. Kundu JK, Chun KS, Kim SO and Surh YJ: Resveratrol inhibits phorbol ester-induced cyclooxygenase-2 expression in mouse skin: MAPKs and AP-1 as potential molecular targets. Biofactors 21: 33-39, 2004.
25. Cao Z, Fang J, Xia C, Shi X and Jiang BH: trans-3,4,5'-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 10: 5253-5263, 2004.
26. Aziz MH, Kumar R and Ahmad N: Cancer chemoprevention by resveratrol: In vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol 23: 17-28, 2003.
27. Jiang H, Zhang L, Kuo J, et al: Resveratrol-induced apoptotic death in human U251 glioma cells. Mol Cancer Ther 4: 554-561, 2005.
28. Wang TT, Schoene NW, Kim EK and Kim YS: Pleiotropic effects of the sirtuin inhibitor sirtinol involves concentration-dependent modulation of multiple nuclear receptor-mediated pathways in androgen-responsive prostate cancer cell LNCaP. Mol Carcinog 52: 676-685, 2013.
29. Juan ME, Alfaras I and Planas JM: Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res 65: 584-591, 2012.
30. Liu P, Wang X, Hu C and Hu T: Inhibition of proliferation and induction of apoptosis by trimethoxyl stilbene (TMS) in a lung cancer cell line. Asian Pac J Cancer Prev 12: 2263-2269, 2011.
31. Zhou JH, Cheng HY, Yu ZQ, He DW, Pan Z and Yang DT: Resveratrol induces apoptosis in pancreatic cancer cells. Chin Med J (Engl) 124: 1695-1699, 2011.
32. Yu HB, Zhang HF, Zhang X, et al: Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism. Hepatogastroenterology 57: 1241-1246, 2010.
33. Li Y, Bäckesjö CM, Haldosén LA and Lindgren U: Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. Eur J Pharmacol 609: 13-18, 2009.
34. Liu Z, Li Y and Yang R: Effects of resveratrol on vascular endothelial growth factor expression in osteosarcoma cells and cell proliferation. Oncol Lett 4: 837-839, 2012.
35. Gusman J, Malonne H and Atassi G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22: 1111-1117, 2001.
36. Aleffi S, Petrai I, Bertolani C, et al: Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42: 1339-1348, 2005.
37. Novo E, Cannito S, Zamara E, et al: Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 170: 1942-1953, 2007.
38. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW and Semenza GL: Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88: 2606-2618, 2000.
39. Zhong H, Chiles K, Feldser D, et al: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000.
40. Zhang Q, Zhang ZF, Rao JY, et al: Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer 111: 849-857, 2004.
41. Akakura N, Kobayashi M, Horiuchi I, et al: Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61: 6548-6554, 2001.
42. Lei J, Ma J, Ma Q, et al: Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Mol Cancer 12: 66, 2013.
43. Krishnamachary B, Berg-Dixon S, Kelly B, et al: Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 1138-1143, 2003.
44. Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558, 2005.
45. Shi XP, Miao S, Wu Y, et al: Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features. Int J Mol Sci 14: 15655-15668, 2013.
46. Shen YA, Lin CH, Chi WH, et al: Resveratrol impedes the stemness, epithelial-mesenchymal transition, and metabolic reprogramming of cancer stem cells in nasopharyngeal carcinoma through p53 activation. Evid Based Complement Alternat Med 2013: 590393, 2013.
47. Li W, Ma J, Ma Q, et al: Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-B pathway. Curr Med Chem 20: 4185-4194, 2013.
48. Tsai JH, Hsu LS, Lin CL, et al: 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Toxicol Appl Pharmacol 272: 746-756, 2013.
49. Wang H, Zhang H, Tang L, et al: Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis. Toxicology 303: 139-146, 2013.
50. Hu FW, Tsai LL, Yu CH, Chen PN, Chou MY and Yu CC: Impairment of tumor-initiating stem-like property and reversal of epithelial-mesenchymal transdifferentiation in head and neck cancer by resveratrol treatment. Mol Nutr Food Res 56: 1247-1258, 2012.
51. Mitchell SH, Zhu W and Young CY: Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59: 5892-5895, 1999.
52. Schneider Y, Vincent F, Duranton B, et al: Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 158: 85-91, 2000.
53. Estrov Z, Shishodia S, Faderl S, et al: Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102: 987-995, 2003.